Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld
Rhea-AI Filing Summary
Aclaris Therapeutics, Inc. reports that Chief Scientific Officer Roland Kolbeck had 36,375 restricted stock units vest and convert into an equal number of common shares on August 1, 2026. Of these, 12,385 shares were withheld by the company at $5.20 per share to satisfy tax withholding obligations. Following the transactions, Kolbeck retains 109,125 restricted stock units, which vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, conditioned on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 23,990 shares
Net Buy
3 txns
Insider
Kolbeck Roland Wilhelm
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F3 | 36,375 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 36,375 | -- | -- |
| Tax Withholding | Common Stock F2 | 12,385 | $5.20 | $64K |
Holdings After Transaction:
Restricted Stock Units — 109,125 shares (Direct);
Common Stock — 23,990 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- F3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Key Figures
RSUs converted to common stock: 36375.0000 shares
Shares withheld for taxes: 12385.0000 shares at $5.2000 per share
RSUs remaining after transaction: 109125.0000 restricted stock units
3 metrics
RSUs converted to common stock
36375.0000 shares
Restricted stock units vesting and converting on August 1, 2026
Shares withheld for taxes
12385.0000 shares at $5.2000 per share
Withheld by issuer to satisfy tax withholding obligations
RSUs remaining after transaction
109125.0000 restricted stock units
Restricted stock units held following the reported transactions
Key Terms
Restricted Stock Units, tax withholding obligations, Continuous Service, derivative security
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations"
Continuous Service financial
"subject to the Continuous Service of the Reporting Person as of each such date"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity activity did Aclaris Therapeutics (ACRS) report for Roland Kolbeck?
Chief Scientific Officer Roland Kolbeck had 36,375 restricted stock units vest and convert into common stock on August 1, 2026. Part of these shares was withheld to cover taxes, with additional restricted stock units continuing to vest over time.
How many restricted stock units does Roland Kolbeck still hold in Aclaris Therapeutics (ACRS)?
After the reported transactions, Roland Kolbeck holds 109,125 restricted stock units. These RSUs vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to his continued service with the company.
Were Roland Kolbeck’s ACRS transactions tied to a Rule 10b5-1 trading plan?
The Form 4 indicates no Rule 10b5-1 trading plan for these transactions, as the related checkbox was not selected. The activity reflects equity award vesting and associated tax withholding rather than sales under a pre-arranged trading program.